Longevica Completes Four-Year Mouse Lifespan Screen Identifying Over 60 Potential Anti-Aging Compounds
The data generated will guide hit-to-lead optimization
Longevica announced the completion of a four-year lifespan study involving 16,000 mice conducted at The Jackson Laboratory, screening for compounds that extend health and lifespan. The $13 million effort identified more than 60 molecules showing life-extending effects in vivo, forming the foundation of a new drug discovery pipeline. The company states this represents the largest in vivo longevity screen to date, focusing on aging mechanisms in mammalian models. Results are now being evaluated for further development into therapeutic candidates targeting age-related decline. The screen prioritized compounds with demonstrated effects on median and maximum lifespan in mice, using standardized protocols to assess both longevity and healthspan indicators. Longevica emphasizes that waiting for animals to age naturally remains a necessary but costly step in validating anti-aging interventions, despite lacking the glamour of faster cellular assays.
Health news
Vegan Diets May Reduce Gut Bacteria Diversity, Study Finds
Music with beats cuts stress hormone more than pink noise
Epigenetic Shifts Can Trigger Liver Cancer Without DNA Damage
Blood Clots and Brain Tumors Linked by Overactive PlateletsThe data generated will guide hit-to-lead optimization, with initial focus on compounds showing consistent effects across sexes and genetic backgrounds. To advance this pipeline, Longevica has formed a new advisory board comprising experts in geroscience, pharmacology, and translational medicine to guide prioritization and development strategy. How Does Longevica Validate Hits From Its Lifespan Screen? Compounds identified in the screen undergo secondary testing for dose response, toxicity, and biomarker changes related to aging pathways such as inflammation and metabolic function. Follow-up studies include longitudinal monitoring of treated mice to confirm sustained effects and assess functional outcomes like grip strength and cognitive performance. Only molecules showing reproducible benefits across multiple validation stages proceed to medicinal chemistry optimization.
The company aims to de-risk candidates early by focusing on targets with clear
The company aims to de-risk candidates early by focusing on targets with clear mechanistic links to aging processes. What Challenges Remain in Translating Mouse Longevity Findings to Humans? Translating lifespan extension from mice to humans faces hurdles including differences in metabolism, lifespan scale, and disease pathology, requiring careful biomarker alignment and phased clinical testing. Longevica acknowledges that mouse data alone cannot predict human outcomes but views it as essential for identifying biologically active compounds worth pursuing in human-relevant models. The company plans to use emerging biomarkers of biological age to bridge preclinical and clinical phases, reducing reliance on waiting for lifespan endpoints in early trials. Success will depend on demonstrating target engagement and safety in human cells and tissues before advancing to patient studies. Frequently Asked Questions How many mice were used in Longevica’s lifespan screen?
The study involved approximately 16,000 mice observed over four years to assess compound effects on natural aging and lifespan. What is the role of the new advisory board? The advisory board provides scientific guidance on compound prioritization, development strategy, and translation of preclinical findings into viable therapeutic candidates. Why does Longevica consider its screen the largest in vivo longevity study? The company states no prior published effort has screened more compounds for lifespan effects in live mammals at this scale, making it the most extensive mammalian aging intervention study reported.